9 Months Ended

Document And Entity Information - shares

Sep. 30, 2019 Nov. 06, 2019
Document Information [Line Items]
Entity Registrant Name GeoVax Labs, Inc.
Entity Central Index Key 0000832489
Current Fiscal Year End Date --12-31
Entity Filer Category Non-accelerated Filer
Entity Current Reporting Status Yes
Entity Emerging Growth Company false
Entity Small Business true
Entity Common Stock, Shares Outstanding (in shares) 426,306,328
Entity Shell Company false
Document Type 10-Q
Document Period End Date Sep. 30,
Document Fiscal Year Focus 2019 2019
Document Fiscal Period Focus Q3
Amendment Flag false
 Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)
ASSETS
Cash and cash equivalents
Grant funds and other receivables
Prepaid expenses and other current assets
Total current assets
Property and equipment, net (Note 5)
Deposits
Total assets
Current liabilities:
Accounts payable
Accrued expenses (Note 6)
Current portion of notes payable (Note 7)
Total current liabilities
Note payable, net of current portion (Note 7)
Total liabilities
Commitments (Note 8)
Stockholders’ equity (deficiency):
Preferred Stock, $.01 par value (Note 9): Authorized shares – 10,000,000 Issued and
outstanding
Common stock, shares – 3,054
$.001 and 3,450
par value: September
Authorized 30,
shares 2019 and December
– 600,000,000 31, 2018,
Issued and outstanding
shares – 95,627,584 and
Additional paid-in capital 437,807 at September 30, 2019 and December 31, 2018, respectively
Accumulated deficit
Total stockholders’ equity (deficiency)
Total liabilities and stockholders’ equity (deficiency)
Sep. 30, 2019 Dec. 31, 2018

$ 569,359 $ 259,701
103,485 121,814
122,746 238,189
795,590 619,704
9,929 11,350
11,010 11,010
816,529 642,064

63,143 125,859
1,732,438 1,238,552
12,500 260,420
1,808,081 1,624,831
29,167 39,580
1,837,248 1,664,411

2,321,823 1,971,333
95,628 438
38,818,750 37,482,766
(42,256,920) (40,476,884)
(1,020,719) (1,022,347)
$ 816,529 $ 642,064
 Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) -
$ / shares
Preferred stock, par value (in dollars per share)
Preferred stock, shares authorized (in shares)
Preferred stock, shares issued (in shares)
Preferred stock, shares outstanding (in shares)
Common stock, par value (in dollars per share)
Common stock, shares authorized (in shares)
Common stock, shares issued (in shares)
Common stock, shares outstanding (in shares)
Sep. 30, 2019 Dec. 31, 2018
$ 0.01 $ 0.01
10,000,000 10,000,000
3,054 3,450
3,054 3,450
$ 0.001 $ 0.001
600,000,000 600,000,000
95,627,584 437,807
95,627,584 437,807
 3 Months Ended
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
Sep. 30, 2019
Grant and collaboration revenue $ 333,209
Operating expenses:
Research and development 467,674
General and administrative 291,475
Total operating expenses 759,149
Loss from operations (425,940)
Other income (expense):
Interest income 2,560
Interest expense (1,054)
Total other income (expense) 1,506
Net loss $ (424,434)
Basic and diluted:
Loss per common share (in dollars per share) $ (0.03)
Weighted averages shares outstanding (in shares) 13,038,871
3 Months Ended 9 Months Ended
Sep. 30, 2018 Sep. 30, 2019 Sep. 30, 2018
$ 349,344 $ 907,382 $ 663,908

557,696 1,474,619 1,416,892

458,974 1,214,189 1,175,399
1,016,670 2,688,808 2,592,291
(667,326) (1,781,426) (1,928,383)

1,058 4,665 4,092

(625) (3,275) (1,458)
433 1,390 2,634
$ (666,893) $ (1,780,036) $ (1,925,749)

$ (1.99) $ (0.37) $ (6.43)

334,814 4,772,648 299,522
 Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficiency)
(Unaudited) - USD ($)
Balance (in shares) at Dec. 31, 2017
Balance at Dec. 31, 2017
Sale of convertible preferred stock for cash (in shares)
Sale of convertible preferred stock for cash
Conversion of preferred stock to common stock (in shares)
Conversion of preferred stock to common stock
Stock option expense
Net loss
Issuance of common stock for services (in shares)
Issuance of common stock for services
Balance (in shares) at Mar. 31, 2018
Balance at Mar. 31, 2018
Balance (in shares) at Dec. 31, 2017
Balance at Dec. 31, 2017
Net loss
Balance (in shares) at Sep. 30, 2018
Balance at Sep. 30, 2018
Balance (in shares) at Mar. 31, 2018
Balance at Mar. 31, 2018
Conversion of preferred stock to common stock (in shares)
Conversion of preferred stock to common stock
Stock option expense
Net loss
Balance (in shares) at Jun. 30, 2018
Balance at Jun. 30, 2018
Sale of convertible preferred stock for cash (in shares)
Sale of convertible preferred stock for cash
Conversion of preferred stock to common stock (in shares)
Conversion of preferred stock to common stock
Stock option expense
Net loss
Balance (in shares) at Sep. 30, 2018
Balance at Sep. 30, 2018
Balance (in shares) at Dec. 31, 2018
Balance at Dec. 31, 2018
Sale of convertible preferred stock for cash (in shares)
Sale of convertible preferred stock for cash
Conversion of preferred stock to common stock (in shares)
Conversion of preferred stock to common stock
Fractional shares issuable upon reverse stock split (in shares)
Fractional shares issuable upon reverse stock split
Stock option expense
Net loss
Balance (in shares) at Mar. 31, 2019
Balance at Mar. 31, 2019
Balance (in shares) at Dec. 31, 2018
Balance at Dec. 31, 2018
Net loss
Issuance of common stock for services (in shares)
Balance (in shares) at Sep. 30, 2019
Balance at Sep. 30, 2019
Balance (in shares) at Mar. 31, 2019
Balance at Mar. 31, 2019
Sale of convertible preferred stock for cash (in shares)
Sale of convertible preferred stock for cash
Conversion of preferred stock to common stock (in shares)
Conversion of preferred stock to common stock
Fractional shares issuable upon reverse stock split (in shares)
Fractional shares issuable upon reverse stock split
Stock option expense
Net loss
Issuance of common stock for services (in shares)
Issuance of common stock for services
Balance (in shares) at Jun. 30, 2019
Balance at Jun. 30, 2019
Sale of convertible preferred stock for cash (in shares)
Sale of convertible preferred stock for cash
Conversion of preferred stock to common stock (in shares)
Conversion of preferred stock to common stock
Stock option expense
Net loss
Issuance of common stock for services (in shares)
Issuance of common stock for services
Balance (in shares) at Sep. 30, 2019
Balance at Sep. 30, 2019
Preferred Stock [Member] Common Stock [Member] Additional Paid-in Capital [Member]
3,670 213,474
$ 1,899,085 $ 213 $ 35,696,435
600
$ 590,000
(450) 60,000
$ (441,000) $ 60 440,940
23,978

10,000
$ 10 199,990
3,820 283,474
$ 2,048,085 $ 283 36,361,343
3,670 213,474
$ 1,899,085 $ 213 35,696,435

3,870 356,807
$ 2,109,085 $ 357 37,008,860
3,820 283,474
$ 2,048,085 $ 283 36,361,343
(345) 46,000
$ (338,100) $ 46 338,054
23,221

3,475 329,474
$ 1,709,985 $ 329 36,722,618
600
$ 600,000
(205) 27,333
$ (200,900) $ 28 200,872
85,370

3,870 356,807
$ 2,109,085 $ 357 37,008,860
3,450 437,807
$ 1,971,333 $ 438 37,482,766
500
$ 404,250 85,750
(767) 118,280
$ (303,475) $ 118 303,357
402

26,652
 3,183 556,489
$ 2,072,108 $ 556 37,898,525
3,450 437,807
$ 1,971,333 $ 438 37,482,766

3,054 95,627,584
$ 2,321,823 $ 95,628 38,818,750
3,183 556,489
$ 2,072,108 $ 556 37,898,525
500
$ 438,700 61,300
(281) 253,300
$ (172,941) $ 254 172,687

26,664

4,127
$4 5,996
3,402 813,916
$ 2,337,867 $ 814 38,165,172
700
$ 700,000
(1,048) 94,775,841
$ (716,044) $ 94,776 621,268
26,348

37,827
$ 38 5,962
3,054 95,627,584
$ 2,321,823 $ 95,628 $ 38,818,750
Retained Earnings [Member] Total

$ (37,916,790) $ (321,057)

590,000

23,978
(621,813) (621,813)

200,000

(38,538,603) (128,892)

(37,916,790) (321,057)
(1,925,749)

(39,842,539) (724,237)

(38,538,603) (128,892)

23,221
(637,043) (637,043)

(39,175,646) (742,714)

600,000

85,370
(666,893) (666,893)

(39,842,539) (724,237)

(40,476,884) (1,022,347)

490,000

26,652
 (701,454) (701,454)

(41,178,338) (1,207,149)

(40,476,884) (1,022,347)
###
41,954

(42,256,920) ###

(41,178,338) (1,207,149)

500,000

26,664
(654,148) (654,148)

6,000

(41,832,486) (1,328,633)

700,000

26,348
(424,434) (424,434)

6,000

$ (42,256,920) ###
 Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
Cash flows from operating activities:
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization
Stock-based compensation expense
Changes in assets and liabilities:
Grant funds and other receivables
Prepaid expenses and other current assets
Accounts payable and accrued expenses
Total adjustments
Net cash used in operating activities
Cash flows from investing activities:
Purchase of property and equipment
Net cash used in investing activities
Cash flows from financing activities:
Net proceeds from sale of preferred stock
Proceeds from issuance of note payable
Principal repayment of note payable
Net cash provided by financing activities
Net increase in cash and cash equivalents
Cash and cash equivalents at beginning of period
Cash and cash equivalents at end of period
 9 Months Ended
Sep. 30, 2019 Sep. 30, 2018

$ (1,780,036) $ (1,925,749)

5,693 14,881
290,744 275,425

18,329 45,001
(83,637) 62,544
431,170 486,413
662,299 884,264
(1,117,737) (1,041,485)

(4,272)
(4,272)

1,440,000 1,190,000
50,000
(8,333)
1,431,667 1,240,000
309,658 198,515
259,701 312,727
$ 569,359 $ 511,242
 Condensed Consolidated Statements of Cash Flows (Unaudited) (Parentheticals) - USD
($)
Conversion of Series C Preferred Stock Into Common Stock [Member]
Convertible preferred stock (in shares)
Conversion of stock, shares issued (in shares)
Conversion of Series C Preferred Stock Into Series F Preferred Stock [Member]
Convertible preferred stock (in shares)
Conversion of Series E Preferred Stock Into Series F Preferred Stock [Member]
Convertible preferred stock (in shares)
Conversion of Series C and Series E Preferred Stock Into Series F Preferred Stock [Member]
Conversion of stock, shares issued (in shares)
Conversion of Series F Preferred Stock Into Common Stock [Member]
Convertible preferred stock (in shares)
Conversion of stock, shares issued (in shares)
Series G Convertible Preferred Stock Issued in Exchange for Cancellation of Term notes
Payable [Member]
Convertible preferred stock (in shares)
Convertible note, value
Conversion from Series F Preferred Stock to Series H Preferred Stock [Member]
Convertible preferred stock (in shares)
Conversion from Series G Preferred Stock to Series H Preferred Stock [Member]
Convertible preferred stock (in shares)
Conversion from Series F and Series G Preferred Stock to Series H Preferred Stock [Member]
Conversion of stock, shares issued (in shares)
Conversion of Series H Preferred Stock Into Common Stock [Member]
Convertible preferred stock (in shares)
Conversion of stock, shares issued (in shares)
Conversion From Series D Convertible Preferred Stock To Common Stock [Member]
Convertible preferred stock (in shares)
Conversion of stock, shares issued (in shares)
 9 Months Ended
Sep. 30, 2019 Sep. 30, 2018

587
78,280

1,563

1,200

2,763

507
381,700

250
$ 250,000

2,256

1,000

3,256

1,002
94,687,441

1,000
133,333
 Note 1 - Description of Business
Notes to Financial Statements
Nature of Operations [Text Block]
 9 Months Ended
Sep. 30, 2019

1. Description of Business GeoVax Labs, Inc. (“GeoVax” or the “Company”), is a clinical-stage

biotechnology company developing immunotherapies and vaccines against cancer and
 Note 2 - Basis of Presentation
Notes to Financial Statements
Basis of Accounting [Text Block]
 9 Months Ended
Sep. 30, 2019

2. Basis of Presentation The accompanying condensed consolidated financial statements at

September 30, 2019 three nine September 30, 2019 2018 not 10 December 31, 2018. not As
 Note 3 - Significant Accounting Policies and Recent Accounting Pronouncements
Notes to Financial Statements
Significant Accounting Policies [Text Block]
 9 Months Ended
Sep. 30, 2019

3. Significant Accounting Policies and Recent Accounting Pronouncements We disclosed in

Note 2 10 December 31, 2018 no 10 In February 2016, No. 2016 02, Leases 2016 02 2016 02
 Note 4 - Basic and Diluted Loss Per Common Share
Notes to Financial Statements
Earnings Per Share [Text Block]
 9 Months Ended
Sep. 30, 2019

4. Basic and Diluted Loss Per Common Share Basic net loss per share is computed using the
weighted-average number of common shares outstanding during the period. Diluted net loss
 Note 5 - Property and Equipment
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]
 9 Months Ended
Sep. 30, 2019

5. Property and Equipment Property and equipment as shown on the accompanying

Condensed Consolidated Balance Sheets is composed of the following as of September 30,
 Note 6 - Accrued Expenses
Notes to Financial Statements
Accounts Payable and Accrued Liabilities Disclosure [Text Block]
 9 Months Ended
Sep. 30, 2019

6. Accrued Expenses Accrued expenses as shown on the accompanying Condensed

Consolidated Balance Sheets is composed of the following as of September 30, 2019 December
 Note 7 - Notes Payable
Notes to Financial Statements
Debt Disclosure [Text Block]
 9 Months Ended
Sep. 30, 2019

7. Notes Payable On February 28, 2018, five $50,000. 5%, second $2,084 2019, $12,500 2020,
2021 2022, $2,083 2023. three nine September 30, 2019 $547 $1,753, $625 $1,458, 2018. On
 Note 8 - Commitments
Notes to Financial Statements
Commitments Disclosure [Text Block]
 9 Months Ended
Sep. 30, 2019

8. Commitments Lease Agreement We lease approximately 8,400 December 31, 2019 three
nine September 30, 2019 $40,316 $120,949, $39,136 $117,409, 2018. $40,316 2019. Other
 Note 9 - Preferred Stock
Notes to Financial Statements
Preferred Stock [Text Block]
 9 Months Ended
Sep. 30, 2019

9. Preferred Stock Prefer red Stock Summary We are authorized to issue up to 10,000,000
$.01 may one September 30, 2019 December 31, 2018. $1,000 three nine September 30, 2019
Note 10 - Common Stock and Stock-based Compensation
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]
 9 Months Ended
Sep. 30, 2019

10. Common Stock and Stock-Based Compensation Reverse Stock Split Following approval by
our shareholders at a meeting held on April 15, 2019, April 30, 2019, one five hundred
 Note 11 - Income Taxes
Notes to Financial Statements
Income Tax Disclosure [Text Block]
 9 Months Ended
Sep. 30, 2019

11. Income Taxes Because of our historically significant net operating losses, we have not 382
 Note 12 - Grants and Collaboration Revenue
Notes to Financial Statements
Government Grants and Contracts [Text Block]
 9 Months Ended
Sep. 30, 2019

12. Grants and Collaboration Revenue We receive payments from government entities under
our grants from the National Institute of Allergy and Infectious Diseases (NIAID) and from the
 Note 13 - Subsequent Events
Notes to Financial Statements
Subsequent Events [Text Block]
 9 Months Ended
Sep. 30, 2019

13. Subsequent Events During October November ( November 6) 2019, 466 330,000,000
October 2019, 678,744
 Note 5 - Property and Equipment (Tables)
Notes Tables
Property, Plant and Equipment [Table Text Block]
 9 Months Ended
Sep. 30, 2019

September 30, 2019 December 31, 2018 Laboratory equipment $ 534,578 $ 530,306
Leasehold improvements 115,605 115,605 Other furniture, fixtures & equipment 28,685
 Note 6 - Accrued Expenses (Tables)
Notes Tables
Schedule of Accrued Liabilities [Table Text Block]
 9 Months Ended
Sep. 30, 2019

September 30, 2019 December 31, 2018 Accrued management salaries $ 1,228,169 $ 924,509
Accrued directors’ fees 378,569 295,670 Other accrued expenses 125,700 18,373 Total
 Note 9 - Preferred Stock (Tables)
Notes Tables
Schedule of Preferred Stock [Table Text Block]
 9 Months Ended
Sep. 30, 2019

September 30, 2019 December 31, 2018 Carrying Carrying Shares Value Shares Value Series
B Convertible Preferred Stock 100 $ 76,095 100 $ 76,095 Series C Convertible Preferred Stock
 Note 2 - Basis of Presentation (Details Textual) Apr. 30, 2019
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio 500
 Note 4 - Basic and Diluted Loss Per Common Share (Details Textual) - shares
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
 3 Months Ended 9 Months Ended
Sep. 30, 2019 Sep. 30, 2018 Sep. 30, 2019 Sep. 30, 2018
10,937,156 86,783 10,895,920 75,740
 Note 5 - Property and Equipment - Schedule of Property and Equipment (Details) - USD
($)
Property and equipment, gross
Accumulated depreciation and amortization
Property and equipment, net
Laboratory Equipment [Member]
Property and equipment, gross
Leasehold Improvements [Member]
Property and equipment, gross
Other Furniture Fixtures And Equipment [Member]
Property and equipment, gross
Sep. 30, 2019 Dec. 31, 2018
$ 678,868 $ 674,596
(668,939) (663,246)
9,929 11,350

534,578 530,306

115,605 115,605

$ 28,685 $ 28,685
 Note 6 - Accrued Expenses - Schedule of Accrued Expenses (Details) - USD ($)
Accrued management salaries
Accrued directors’ fees
Other accrued expenses
Total accrued expenses
Sep. 30, 2019 Dec. 31, 2018
$ 1,228,169 $ 924,509
378,569 295,670
125,700 18,373
$ 1,732,438 $ 1,238,552
 Note 7 - Notes Payable (Details Textual) - USD ($)
Proceeds from Notes Payable, Total
Interest Expense, Total
Term Notes [Member]
Debt Instrument, Face Amount
Senior Notes [Member]
Debt Instrument, Term
Proceeds from Notes Payable, Total
Debt Instrument, Interest Rate, Stated Percentage
Long-term Debt, Maturities, Repayments of Principal, Remainder of Fiscal Year
Long-term Debt, Maturities, Repayments of Principal in Year Two
Long-term Debt, Maturities, Repayments of Principal in Year Five
Interest Expense, Total
Long-term Debt, Maturities, Repayments of Principal in Year Three
Long-term Debt, Maturities, Repayments of Principal in Year Four
 Feb. 28, 2018 Sep. 30, 2019 Sep. 30, 2018 Sep. 30, 2019 Sep. 30, 2018 Dec. 27, 2018
$ 50,000
$ 1,054 $ 625 3,275 1,458

$ 250,000

5 years
$ 50,000
5.00%
2,084 2,084
12,500 12,500
2,083 2,083
547 $ 625 1,753 $ 1,458
12,500 12,500
$ 12,500 $ 12,500
 Note 8 - Commitments (Details Textual)
Area of Real Estate Property | ft²
Operating Leases, Rent Expense, Total
Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year
Unrecorded Unconditional Purchase Obligation, Total
 3 Months Ended 9 Months Ended
Sep. 30, 2019USD ($) Sep. 30, 2018USD ($) Sep. 30, 2019USD ($) Sep. 30, 2018USD ($)

$ 40,316 $ 39,136 $ 120,949 $ 117,409

40,316 40,316
$ 391,000 $ 391,000
Jun. 30, 2019ft²
8,400
 Note 9 - Preferred Stock (Details Textual) - USD ($)
Preferred Stock, Shares Authorized
Preferred Stock, Par or Stated Value Per Share
Preferred Stock, Shares Outstanding, Ending Balance
Series I Warrants [Member]
Convertible Preferred Stock and Related Warrants Issued
Class of Warrant or Right, Exercise Price of Warrants or Rights
Class of Warrant or Right, Number of Securities Called by Warrants or Rights
Series G Warrants [Member]
Warrants and Rights Outstanding, Term
Series G Convertible Preferred Stock and Related Warrants [Member]
Convertible Preferred Stock and Related Warrants, Authorized
Proceeds from Issuance of Convertible Preferred Stock and Related Warrants, Maximum
Convertible Preferred Stock and Related Warrants Issued
Conversion of Series C Preferred Stock Into Common Stock [Member]
Conversion of Stock, Shares Converted
Conversion of Stock, Shares Issued
Conversion of Series C Preferred Stock Into Series F Preferred Stock [Member]
Conversion of Stock, Shares Converted
Conversion of Series E Preferred Stock Into Series F Preferred Stock [Member]
Conversion of Stock, Shares Converted
Conversion of Series F Preferred Stock Into Common Stock [Member]
Conversion of Stock, Shares Converted
Conversion of Stock, Shares Issued
Conversion from Series F Preferred Stock to Series H Preferred Stock [Member]
Conversion of Stock, Shares Converted
Conversion from Series F and Series G Preferred Stock to Series H Preferred Stock [Member]
Conversion of Stock, Shares Issued
Conversion of Series H Preferred Stock Into Common Stock [Member]
Conversion of Stock, Shares Converted
Conversion of Stock, Shares Issued
Conversion of Series I Preferred Stock [Member]
Conversion of Stock, Shares Converted
Series B Convertible Preferred Stock [Member]
Preferred Stock, Par or Stated Value Per Share
Conversion of Stock, Shares Converted
Preferred Stock, Shares Outstanding, Ending Balance
Convertible Preferred Stock, Conversion Price1
Series E Convertible Preferred Stock [Member]
Preferred Stock, Par or Stated Value Per Share
Conversion of Stock, Shares Converted
Preferred Stock, Shares Outstanding, Ending Balance
Series F Convertible Preferred Stock [Member]
Preferred Stock, Par or Stated Value Per Share
Convertible Preferred Stock, Conversion Price1
Number of Series C and Series E Preferred Stock Exchanged for Series F Convertible Preferred
Stock
Convertible Preferred Stock, Conversion Price, Percentage of Volume Weighted Average Price
of the Common
Series StockPreferred Stock [Member]
G Convertible
Preferred Stock, Par or Stated Value Per Share
Preferred Stock, Shares Outstanding, Ending Balance
Convertible Preferred Stock, Conversion Price1
Convertible Preferred Stock, Conversion Price, Percentage of Volume Weighted Average Price
of the Common
Series StockPreferred Stock [Member]
H Convertible
Preferred Stock, Par or Stated Value Per Share
Preferred Stock, Shares Outstanding, Ending Balance
Convertible Preferred Stock, Conversion Price1
Series I Convertible Preferred Stock [Member]
Preferred Stock, Par or Stated Value Per Share
Preferred Stock, Shares Outstanding, Ending Balance
Convertible Preferred Stock, Conversion Price1
Stock Issued During Period, Shares, New Issues
Proceeds from Issuance of Preferred Stock and Preference Stock
Series C Convertible Preferred Stock [Member]
Preferred Stock, Par or Stated Value Per Share
Preferred Stock, Shares Outstanding, Ending Balance
Jul. 24, 2019 Jul. 16, 2019 Jun. 19, 2019 Apr. 26, 2019 Feb. 26, 2019 Feb. 25, 2019

33,334
$ 7.50
66,668

5 years

1,000
$ 500,000 $ 500,000 $ 250,000 $ 1,000,000
500 500 500

3,256
 $ 1,000

$ 7.50
90.00%

$ 1,000

$ 7.50

$ 1,000

$ 7.50
700
$ 700,000
Feb. 18, 2019 Jul. 31, 2019 Feb. 28, 2019 Feb. 28, 2019 Sep. 30, 2019 Sep. 30, 2019
10,000,000 10,000,000
$ 0.01 $ 0.01
3,054 3,054

587 587
78,280 78,280

1,563 1,563

1,200 1,200

46 507
88,400 381,700

2,256 2,256

3,256

1,002 1,002
94,687,441 94,687,441

$ 1,000 $ 1,000
0
100 100
$ 175 $ 175

$ 1,000 $ 1,000
0
 $ 1,000 $ 1,000 $ 1,000
$ 7.50
2,763
90.00%

$ 1,000 $ 1,000
1,000

2,254 2,254

700 700

$ 1,000 $ 1,000
Dec. 31, 2018
10,000,000
$ 0.01
3,450

100

1,200
2,150
 Note 9 - Preferred Stock - Preferred Stock Summary (Details) - USD ($) Sep. 30, 2019
Preferred stock, shares outstanding (in shares) 3,054
Preferred Stock $ 2,321,823
Series B Convertible Preferred Stock [Member]
Preferred stock, shares outstanding (in shares) 100
Preferred Stock $ 76,095
Series C Convertible Preferred Stock [Member]
Preferred stock, shares outstanding (in shares)
Preferred Stock
Series E Convertible Preferred Stock [Member]
Preferred stock, shares outstanding (in shares)
Preferred Stock
Series H Convertible Preferred Stock [Member]
Preferred stock, shares outstanding (in shares) 2,254
Preferred Stock $ 1,545,728
Series I Convertible Preferred Stock [Member]
Preferred stock, shares outstanding (in shares) 700
Preferred Stock $ 700,000
Dec. 31, 2018
3,450
$ 1,971,333

100
$ 76,095

2,150
$ 705,238

1,200
$ 1,190,000
 Note 10 - Common Stock and Stock-based Compensation (Details Textual)
Stock Issued During Period, Shares, Issued for Services
Share-based Compensation Arrangement by Share-based Payment Award, Options,
Outstanding, Number, Ending
Share-based Compensation Balance
Arrangement by Share-based Payment Award, Options,
Outstanding, Weighted Average Exercise Price, Ending Balance
Share-based Compensation Arrangement by Share-based | $ /Award,
Payment shares Options,
Exercisable,
Share-based Number
Compensation Arrangement by Share-based Payment Award, Options,
Exercisable,
Share-based Weighted Average Exercise
Payment Arrangement, Price | $Award,
Nonvested / shares
Cost Not yet Recognized, Amount,
Total | $
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for
Recognition
Stock Issued During Period, Value Expensed During the Period, Issued for Services | $
Share-based Payment Arrangement, Option [Member]
Share-based Payment Arrangement, Expense | $
Common Stock Purchase Warrants [Member]
Class Of Warrant Or Right Issued During Period
Class of Warrant or Right, Outstanding
Class Of Warrant Or Right Outstanding Weighted Average Exercise Price | $ / shares
Class Of Warrant Or Right Exercisable Number
Class Of Warrant Or Right Exercisable Weighted Average Exercise Price | $ / shares
Conversion from Series C, F and H Convertible Preferred Stock to Common Stock [Member]
Conversion of Stock, Shares Issued
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio
Apr. 30, 2019 Sep. 30, 2019USD ($)$ / sharesshares Sep. 30, 2018USD ($)

28,800
$ 53.99
13,585
$ 93.92
$ 130,719

6,000 $ 57,143

$ 26,348 $ 85,370

294,302
$ 7.50
227,634
$ 7.50

500
 Sep. 30, 2019USD ($)$ / sharesshares Sep. 30, 2018USD ($)
41,954
28,800
$ 53.99
13,585
$ 93.92
$ 130,719
1 year 219 days
$ 211,080 $ 142,856

$ 79,664 $ 132,569

100,002
294,302
$ 7.50
227,634
$ 7.50

95,147,421
 3 Months Ended
Note 12 - Grants and Collaboration Revenue (Details Textual) - USD ($)
Sep. 30, 2019
Revenue from Contract with Customer, Including Assessed Tax $ 333,209
NIH Grants [Member]
Revenue from Contract with Customer, Including Assessed Tax 214,765
Unused Grant Funds 1,835,225
Research Agreements [Member]
Revenue from Contract with Customer, Including Assessed Tax $ 118,444
3 Months Ended 9 Months Ended
Sep. 30, 2018 Sep. 30, 2019 Sep. 30, 2018
$ 349,344 $ 907,382 $ 663,908

340,716 754,022 650,280

1,835,225

$ 8,628 $ 153,360 $ 13,628

 Note 13 - Subsequent Events (Details Textual) - shares
Stock Issued During Period, Shares, Issued for Services
Subsequent Event [Member]
Stock Issued During Period, Shares, Issued for Services
Conversion of Series H Preferred Stock Into Common Stock [Member]
Conversion of Stock, Shares Converted
Conversion of Stock, Shares Issued
Conversion of Series H Preferred Stock Into Common Stock [Member] | Subsequent Event
[Member]
Conversion of Stock, Shares Converted
Conversion of Stock, Shares Issued
 1 Months Ended 3 Months Ended 9 Months Ended
Nov. 06, 2019 Oct. 31, 2019 Sep. 30, 2019 Sep. 30, 2019
41,954

678,744

1,002 1,002
94,687,441 94,687,441

466
330,000,000